PRELID1 Antibody

What is PRELID1 and why is it important in cellular research?

PRELID1 (PRELI domain-containing protein 1) is a 25 kDa mitochondrial protein that plays crucial roles in modulating mitochondrial apoptotic pathways by ensuring cardiolipin accumulation in mitochondrial membranes . It functions as part of the TRIAP1:PRELID1 complex which mediates phosphatidic acid (PA) transfer between liposomes, likely serving as a PA transporter across the mitochondrial intermembrane space to provide PA for cardiolipin synthesis in the inner membrane . PRELID1 is particularly significant in immunological research as it regulates Th cell differentiation by down-regulating STAT6, thereby reducing IL-4-induced Th2 cell numbers . Its importance extends to developmental biology, as it may play critical roles in the development of vital and immunocompetent organs . The involvement of PRELID1 in mitochondrial phospholipid transport connects it to conditions where proteins like tafazzin participate in cardiolipin remodeling, highlighting its relevance to maintaining healthy mitochondrial dynamics .

What types of PRELID1 antibodies are available for research applications?

Current research-grade PRELID1 antibodies fall into two primary categories with distinct advantages for different experimental applications:

The choice between monoclonal and polyclonal antibodies should be guided by your specific experimental requirements, with monoclonals offering higher specificity while polyclonals provide broader epitope recognition and potential signal amplification for low-abundance targets .

How should I select the appropriate PRELID1 antibody for my specific research application?

When selecting a PRELID1 antibody, consider these critical parameters to ensure experimental success:

• Application compatibility: Verify that the antibody has been validated for your intended application. For example, Proteintech's 10877-1-AP is validated for WB, IHC, and ELISA , while OriGene's OTI2A6 is validated for IHC(P) and WB .

• Species reactivity: Most commercial PRELID1 antibodies are validated against human samples . If working with non-human systems, select antibodies with predicted cross-reactivity based on sequence homology or explicit validation data. For instance, Abbexa's antibody is predicted to react with mouse PRELID1 .

• Epitope location: Consider whether your experimental conditions might mask or alter specific epitopes. The Abcam antibody (ab196275) targets amino acids 50-200 of PRELID1 , while Abbexa's antibody targets the N-terminal region (amino acids 27-54) .

• Validation evidence: Review validation data such as Western blot images, IHC staining patterns, or citation records. For example, Proteintech's antibody has been cited in publications related to hepatocellular carcinoma research .

• Experimental conditions: Match antibody formulation to your protocol requirements. Most PRELID1 antibodies are supplied in PBS with stabilizers like glycerol and require storage at -20°C with minimal freeze-thaw cycles .

Creating a comparison matrix of these factors for available antibodies will facilitate selection of the optimal reagent for your specific research context.

What are the optimal protocols for using PRELID1 antibodies in Western blotting?

For optimal Western blot detection of PRELID1, follow these evidence-based recommendations:

• Sample preparation:

  • Use fresh tissue/cells when possible to minimize protein degradation

  • Include protease inhibitors in lysis buffer to protect the 25 kDa PRELID1 protein

  • For mitochondrial enrichment, consider subcellular fractionation techniques

• Loading and transfer considerations:

  • Load 20-30 μg of total protein per lane

  • Use 12-15% polyacrylamide gels to optimally resolve the 25 kDa PRELID1 protein

  • Transfer to PVDF membranes (0.2 μm pore size) for optimal protein binding

• Antibody dilutions and incubation:

  • For Abbexa's polyclonal antibody: 1:1000 dilution

  • For Abcam's polyclonal antibody: 1:5 dilution, though this should be verified

  • Incubate primary antibody overnight at 4°C for optimal binding

  • For secondary antibody, use a 1:5000-1:10000 dilution with 1-hour incubation at room temperature

• Detection and troubleshooting:

  • For low abundance detection, consider using enhanced chemiluminescence systems

  • If high background occurs, increase blocking time/concentration and implement additional wash steps

  • If detecting a band different from the expected 25 kDa size, consider potential post-translational modifications or splice variants

These recommendations should be optimized for your specific experimental conditions and sample types to ensure reproducible PRELID1 detection .

How can I optimize immunohistochemistry protocols for PRELID1 detection in tissue samples?

Successful IHC detection of PRELID1 in tissue samples depends on these critical optimization parameters:

• Tissue preparation and antigen retrieval:

  • For PRELID1 detection in human tissue samples, formalin-fixed paraffin-embedded (FFPE) sections are commonly used

  • Proteintech recommends antigen retrieval with TE buffer pH 9.0, with citrate buffer pH 6.0 as an alternative

  • Complete epitope unmasking is critical as PRELID1 is primarily localized to mitochondria

• Antibody selection and dilution:

  • For OriGene's monoclonal antibody OTI2A6: Follow manufacturer's recommended dilution

  • For Proteintech's polyclonal antibody 10877-1-AP: Use 1:20-1:200 dilution range

  • For Sigma-Aldrich's antibody HPA005701: Use 1:50-1:200 dilution

  • Titrate antibodies in each testing system to determine optimal concentration

• Detection and visualization systems:

  • Use polymer-based detection systems for enhanced sensitivity

  • DAB (3,3'-diaminobenzidine) provides good contrast for brightfield microscopy

  • Include positive controls such as human breast cancer, colon cancer, or liver cancer tissues, which have shown positive IHC staining with PRELID1 antibodies

  • Include a negative control by omitting primary antibody

• Result interpretation:

  • Expect primarily cytoplasmic staining pattern consistent with mitochondrial localization

  • The staining intensity may vary based on tissue type and cellular metabolic state

  • Validate findings by correlating with other mitochondrial markers

Careful optimization of these parameters will ensure specific and reproducible PRELID1 detection in your tissue samples .

What considerations are important for immunofluorescence applications using PRELID1 antibodies?

When designing immunofluorescence experiments to visualize PRELID1, consider these technical aspects:

• Fixation and permeabilization optimization:

  • For mitochondrial proteins like PRELID1, use paraformaldehyde fixation (4%, 15 minutes) followed by gentle permeabilization with 0.1-0.3% Triton X-100

  • Over-permeabilization can disrupt mitochondrial architecture, while insufficient permeabilization may prevent antibody access

  • Alternative fixatives such as methanol may be suitable if paraformaldehyde masks epitopes

• Antibody selection and dilution:

  • For Sigma-Aldrich's HPA005701 antibody, use 0.25-2 μg/mL concentration for optimal staining

  • Include mitochondrial counterstains (e.g., MitoTracker dyes or antibodies against established mitochondrial markers) to confirm subcellular localization

  • For cultured cells, seed at 50-70% confluence to enable clear visualization of mitochondrial networks

• Signal amplification and imaging parameters:

  • Use high numerical aperture objectives (60-100×) to resolve mitochondrial structures

  • Consider deconvolution or super-resolution microscopy techniques for detailed subcellular localization

  • For weak signals, try tyramide signal amplification while maintaining specificity

  • Z-stack imaging is recommended to capture the full three-dimensional mitochondrial network

• Co-localization analysis:

  • When performing co-localization studies with other mitochondrial proteins, analyze using appropriate software (ImageJ with Coloc2, CellProfiler, etc.)

  • Calculate Pearson's or Mander's coefficients to quantify co-localization with other mitochondrial markers

  • Control for random co-localization using computational approaches such as pixel randomization

These methodological considerations will enable precise subcellular localization of PRELID1 and facilitate studies of its interactions with other mitochondrial components .

How can I address common issues with PRELID1 antibody specificity and sensitivity?

When encountering specificity or sensitivity challenges with PRELID1 antibodies, implement these systematic troubleshooting approaches:

• Antibody validation strategies:

  • Perform peptide competition assays using the immunizing peptide to confirm specificity

  • Compare staining patterns across multiple PRELID1 antibodies targeting different epitopes

  • Include PRELID1 knockout or knockdown samples as negative controls

  • For the Abbexa antibody, which uses a synthetic peptide (aa 27-54) as immunogen, peptide blocking is particularly valuable

• Cross-reactivity assessment:

  • Examine potential cross-reactivity with other PRELI domain-containing proteins (PRELID1, PRELID2, PRELID3A, PRELID3B)

  • Review antibody immunogen sequences for homology with related proteins

  • The monoclonal antibody from OriGene may offer higher specificity than polyclonal alternatives in cases where cross-reactivity is a concern

• Signal optimization approaches:

  • For weak signals, extend primary antibody incubation time or increase concentration within recommended ranges

  • Try signal amplification systems (e.g., biotin-streptavidin enhancement)

  • Adjust antigen retrieval conditions by testing multiple buffers and pH values

  • For Proteintech's antibody, test both the recommended TE buffer pH 9.0 and alternative citrate buffer pH 6.0

• Background reduction strategies:

  • Increase blocking duration (1-2 hours at room temperature)

  • Try alternative blocking agents (5% non-fat dry milk, 5% BSA, commercial blockers)

  • Implement additional washing steps with increased duration

  • Dilute secondary antibody further to reduce non-specific binding

Systematic implementation of these approaches will help distinguish true PRELID1 signal from artifacts and cross-reactivity issues .

What are the critical storage and handling considerations for maintaining PRELID1 antibody performance?

Proper handling and storage of PRELID1 antibodies is essential for maintaining their functionality and experimental reproducibility:

• Storage temperature and conditions:

  • Store all PRELID1 antibodies at -20°C as consistently recommended across manufacturers

  • The common storage buffer formulation includes PBS with stabilizers such as glycerol (typically 50%) and sodium azide (0.02-0.09%)

  • Avoid repeated freeze-thaw cycles that can cause antibody degradation and loss of activity

• Aliquoting recommendations:

  • Upon receipt, divide antibodies into small single-use aliquots

  • Calculate aliquot volumes based on your experimental needs (typically 10-20 μL)

  • Use sterile microcentrifuge tubes specifically designed for protein storage

  • The Proteintech antibody documentation notes that aliquoting is unnecessary for -20°C storage, though this contradicts general best practices

• Working dilution preparation:

  • Prepare fresh working dilutions on the day of experiment

  • Use high-quality diluents free of contamination

  • Allow antibodies to thaw completely at 4°C before dilution

  • Avoid vortexing antibodies; instead, mix by gentle inversion or flicking

• Expiration and functionality monitoring:

  • Document date of receipt and first use of each antibody

  • Include positive controls in each experiment to monitor antibody performance over time

  • The Proteintech antibody is reported stable for one year after shipment when stored properly

  • Consider implementing a quality control system with regular validation of antibody performance

Following these storage and handling practices will maximize antibody shelf-life and ensure consistent experimental results across your research timeline .

How should discrepancies in PRELID1 detection between different antibodies be interpreted?

When different PRELID1 antibodies yield discrepant results, apply this systematic analytical framework:

• Epitope mapping analysis:

  • Map the epitopes recognized by each antibody to determine if they target different regions of PRELID1

  • OriGene's monoclonal antibody targets a specific epitope recognized by the OTI2A6 clone

  • Abcam's antibody recognizes amino acids 50-200 , while Abbexa's targets amino acids 27-54

  • Epitope accessibility may differ in various experimental conditions or tissue types

• Post-translational modification considerations:

  • Determine if potential phosphorylation, glycosylation, or other modifications might affect epitope recognition

  • Consider if proteolytic processing could generate fragments detectable by some antibodies but not others

  • The calculated molecular weight of PRELID1 is 25 kDa, so significant deviations may indicate modifications

• Splice variant detection:

  • Review literature and databases for known PRELID1 splice variants

  • Correlate antibody recognition patterns with predicted splice variant expression in your experimental system

  • Design validation experiments using recombinant proteins representing specific splice variants

• Methodological analysis framework:

  • Create a comparative analysis table documenting all variables:

    • Antibody type, clone, and manufacturer

    • Experimental conditions (fixation, antigen retrieval, detection method)

    • Sample type and preparation method

    • Detection patterns observed

  • Systematically modify one variable at a time to identify factors causing discrepancies

  • Consider that monoclonal antibodies like OTI2A6 may provide more consistent results between experiments but might miss some forms of the protein

This structured approach will help determine whether discrepancies represent technical artifacts or biologically meaningful variations in PRELID1 expression, processing, or modification .

How can PRELID1 antibodies be utilized in studies of mitochondrial phospholipid transport and membrane dynamics?

PRELID1 antibodies can be strategically employed to investigate mitochondrial phospholipid transport mechanisms:

• Co-immunoprecipitation approaches:

  • Use PRELID1 antibodies to pull down protein complexes involved in phospholipid transport

  • Identify PRELID1 interaction partners by mass spectrometry

  • Specifically examine the TRIAP1:PRELID1 complex formation, which mediates phosphatidic acid transfer between liposomes

  • Combine with lipid analysis to correlate protein interactions with phospholipid transfer activity

• Super-resolution microscopy applications:

  • Employ techniques such as STED, PALM, or STORM with fluorescently-labeled PRELID1 antibodies

  • Map the precise localization of PRELID1 within the mitochondrial intermembrane space

  • Perform dual-color imaging with cardiolipin markers to visualize spatial relationships

  • Analyze dynamics using live-cell compatible antibody fragments or nanobodies

• Proximity ligation assays:

  • Investigate protein-protein interactions between PRELID1 and components of the mitochondrial phospholipid transport machinery

  • Combine PRELID1 antibodies with antibodies against proteins like TRIAP1, tafazzin, or other phospholipid metabolism enzymes

  • Quantify interaction signals in different cellular conditions or disease models

• Correlative microscopy approaches:

  • Use PRELID1 antibodies for immunogold labeling in electron microscopy

  • Correlate fluorescence microscopy with electron microscopy to link PRELID1 distribution with mitochondrial ultrastructure

  • Examine PRELID1 localization relative to contact sites between mitochondria and other organelles

These advanced applications provide mechanistic insights into PRELID1's role in maintaining mitochondrial membrane composition and dynamics, particularly in the context of cardiolipin synthesis and accumulation .

What are the current approaches for studying PRELID1's role in apoptotic pathways and Th cell differentiation?

Investigating PRELID1's regulatory functions in apoptosis and immune cell differentiation requires sophisticated experimental approaches:

• Flow cytometry and cell sorting strategies:

  • Combine surface markers with intracellular PRELID1 staining in T cell populations

  • Use fixation and permeabilization protocols optimized for mitochondrial proteins

  • Correlate PRELID1 expression with apoptotic markers (Annexin V, active caspases) and T helper cell subtype markers

  • Sort T cell populations based on PRELID1 expression levels for further functional analyses

• ChIP-seq and transcriptomic analyses:

  • Examine STAT6 binding patterns in cells with normal vs. altered PRELID1 expression

  • Conduct RNA-seq to identify genes differentially regulated downstream of PRELID1-mediated STAT6 suppression

  • Integrate ChIP-seq and RNA-seq data to construct regulatory networks connecting PRELID1 to Th cell differentiation pathways

  • The known role of PRELID1 in down-regulating STAT6 and reducing IL-4-induced Th2 cell numbers provides a foundation for these analyses

• Mitochondrial apoptotic pathway probing:

  • Use PRELID1 antibodies alongside markers of mitochondrial membrane potential

  • Combine with cytochrome c release assays to correlate PRELID1 levels with apoptotic events

  • Implement live-cell imaging to track temporal relationships between PRELID1 localization and apoptotic signaling

  • Examine cardiolipin distribution and oxidation state as a function of PRELID1 expression

• Advanced genetic modification approaches:

  • Employ CRISPR/Cas9 to generate conditional PRELID1 knockout in specific T cell populations

  • Create domain-specific mutations to dissect functional regions of PRELID1

  • Develop reporter systems to monitor PRELID1 expression during T cell activation and differentiation

  • Combine with lineage tracing to track the fate of cells with different PRELID1 expression levels

These methodologies enable mechanistic studies of how PRELID1 integrates mitochondrial phospholipid homeostasis with immune cell differentiation and apoptotic regulation .

How can PRELID1 antibodies contribute to understanding mitochondrial dysfunction in disease contexts?

PRELID1 antibodies provide valuable tools for investigating mitochondrial dysfunction across diverse pathological conditions:

• Clinical tissue microarray applications:

  • Evaluate PRELID1 expression patterns across tissue microarrays from various diseases

  • Correlate expression with clinical outcomes and treatment responses

  • Known positive IHC detection in human breast cancer, colon cancer, and liver cancer tissues suggests relevance to oncological research

  • Analyze co-expression with other mitochondrial proteins to identify disease-specific patterns

• Neurodegenerative disease research applications:

  • Examine PRELID1 expression and localization in neuronal populations vulnerable to mitochondrial dysfunction

  • Compare PRELID1-mediated phospholipid transport in models of Parkinson's, Alzheimer's, and other neurodegenerative conditions

  • Investigate relationships between PRELID1 function and mitochondrial dynamics (fission, fusion, mitophagy) in neuronal cells

  • The connection between PRELID1 and cardiolipin metabolism suggests potential implications for neurodegeneration where mitochondrial membrane integrity is compromised

• Cardiovascular pathology investigations:

  • Assess PRELID1 expression in cardiomyocytes under ischemic conditions

  • Examine the relationship between PRELID1, cardiolipin composition, and cardiac function

  • Compare PRELID1 activity with other cardiolipin-remodeling proteins like tafazzin

  • The documented role of proteins like tafazzin in cardiolipin remodeling highlights potential cardiovascular relevance for PRELID1 research

• Cancer metabolism profiling:

  • Use PRELID1 antibodies to study mitochondrial adaptations in cancer cells

  • Combine with metabolic flux analysis to correlate PRELID1 expression with cancer cell bioenergetics

  • Investigate PRELID1's relationship with mitochondrial membrane composition in treatment-resistant cancer cells

  • The publication cited by Proteintech regarding PRELID1 in hepatocellular carcinoma immune gene signatures suggests oncological applications

These applications illustrate how PRELID1 antibodies can advance our understanding of mitochondrial phospholipid dysregulation across multiple disease contexts, potentially revealing new diagnostic markers or therapeutic targets .

What new methodologies are being developed to study PRELID1 interactions with other proteins and lipids?

Cutting-edge techniques are expanding our ability to investigate PRELID1's molecular interactions:

• Proximity-dependent labeling approaches:

  • Implement BioID or APEX2 fusion constructs with PRELID1 to identify proximal proteins in living cells

  • These approaches provide temporal snapshots of the PRELID1 interactome under various cellular conditions

  • Compare interactomes between normal and stressed mitochondria to identify stress-specific interactions

  • Particularly useful for capturing transient interactions during phospholipid transfer events

• Advanced lipidomic integration techniques:

  • Combine PRELID1 immunoprecipitation with lipidomic analysis to identify associated lipid species

  • Implement click-chemistry approaches to track phosphatidic acid transfer mediated by the TRIAP1:PRELID1 complex

  • Correlate structural variations in PRELID1 with changes in lipid binding profiles

  • These approaches can validate and extend current understanding of PRELID1's role in phosphatidic acid transport

• Single-molecule microscopy methods:

  • Apply techniques like single-particle tracking to monitor PRELID1 dynamics at the nanoscale

  • Implement fluorescence correlation spectroscopy to measure diffusion coefficients and binding kinetics

  • Use Förster resonance energy transfer (FRET) to examine conformational changes during lipid binding

  • These approaches provide mechanistic insights into the spatial and temporal dynamics of PRELID1 function

• Structural biology integration:

  • Combine antibody epitope mapping with structural data to create comprehensive protein interaction models

  • Implement hydrogen-deuterium exchange mass spectrometry with PRELID1 antibodies to probe conformational dynamics

  • Correlate antibody recognition patterns with structural changes induced by lipid binding

  • These integrative approaches link antibody-based detection to molecular mechanism

These emerging methodologies expand our toolbox for investigating the molecular mechanisms underlying PRELID1's role in phospholipid transport and mitochondrial membrane maintenance, potentially revealing new therapeutic targets for diseases involving mitochondrial dysfunction .

How can PRELID1 antibodies contribute to translational research and biomarker development?

PRELID1 antibodies have significant potential in translational applications spanning diagnostics to therapeutic development:

• Biomarker validation workflows:

  • Develop standardized IHC protocols for PRELID1 detection in clinical specimens

  • Establish scoring systems correlating PRELID1 expression with disease progression

  • Conduct retrospective studies on tissue microarrays to correlate PRELID1 levels with patient outcomes

  • The demonstrated utility of PRELID1 antibodies in human cancer tissues supports these applications

• Liquid biopsy applications:

  • Investigate PRELID1 detection in circulating tumor cells or extracellular vesicles

  • Develop sensitive immunoassays for PRELID1 quantification in biological fluids

  • Compare PRELID1 levels with established biomarkers for mitochondrial dysfunction

  • These approaches could enable minimally invasive monitoring of diseases involving mitochondrial stress

• Therapeutic response monitoring:

  • Use PRELID1 antibodies to assess mitochondrial adaptations during treatment with metabolic or mitochondria-targeting therapies

  • Develop companion diagnostic applications for drugs affecting mitochondrial phospholipid metabolism

  • Implement multiplexed imaging to correlate PRELID1 with other markers of treatment response

  • Such applications could guide personalized treatment approaches in diseases with mitochondrial involvement

• Antibody-drug conjugate development:

  • Evaluate PRELID1 antibodies for potential targeting of dysfunctional mitochondria

  • Assess internalization kinetics of antibodies binding to externalized PRELID1 during mitochondrial stress

  • Screen antibody clones for optimal targeting properties in disease models

  • These therapeutic applications represent longer-term potential for PRELID1 research

These translational research directions highlight how PRELID1 antibodies can bridge fundamental mitochondrial biology with clinical applications, particularly in diseases where mitochondrial phospholipid dysregulation contributes to pathogenesis .